According to FDA data, the agency issued a safety warning on GLP-1 medications due to a rare risk of non-arteritic anterior ischemic optic neuropathy (NAION). The condition affects approximately 6 individuals per 100,000 annually among users of these drugs and can cause permanent vision loss. The FDA has required manufacturers of major GLP-1 drugs including Ozempic and Zepbound to add new warning labels to their products.

View Source

Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.